[논문]Venlafaxine의 안면홍조 증상개선효과에 대한 최근 연구 고찰

이유정

Venlafaxine의 안면홍조 증상개선효과에 대한 최근 연구 고찰
Venlafaxine for Management of Hot Flashes: A Review of Randomized Controlled Trials in Human 원문보기

한국임상약학회지 = Korean journal of clinical pharmacy, v.20 no.2, 2010년, pp.138 - 144

초록
AI-Helper

안면홍조는 폐경기 초기 많은 여성들에게 나타나는 증상이다. 정확한 원인은 밝혀지지 않았지만 혈중 에스트로겐 수치가 낮아졌을 때 안면홍조 증상이 나타나기 때문에 에스트로겐을 기본으로 한 호르몬 요법이 수년간 안면홍조 증상치료의 중심이었다. 그러나 호르몬 요법이 유방암, 뇌졸중 등의 발생 위험도를 증가시킨다는 연구 결과가 발표된 이후 많은 보건의료인들은 호르몬 요법 대신 사용 가능한 다른 치료제에 관심을 보이고 있다. 본 연구는 venlafaxine의 안면홍조 증상 치료효과에 대한 최신 지견을 얻고자, 1990년부터 2010년 7월까지 MEDLINE에 등재된 논문을 Hot flashes와 Venlafaxine이라는 MeSH terms로 검색하여 추출한 자료 중에서 대조군이 사용된 무작위 배정 및 이중맹검 임상연구 사례만을 선별하여 임상적 유용성을 평가하였다. 현재 venlafaxine은 안면홍조 증상 치료제로 허가된 의약품은 아니지만 최근 여러 국가에서 시행된 연구들은 venlafaxine이 효과적인 안면홍조 증상 치료제일 수 있다는 결과를 보여주고 있다.

Abstract ▼ AI-Helper

The results from eight randomized controlled studies demonstrate that venlafaxine is effective in the treatment of hot flashes with tolerable adverse effects. Based on the results of the above studies, venlafaxine can be recommended for the treatment of hot flashes. However, there are limitations in the above studies. The inclusion criteria of 5 studies reviewed in this paper was breast cancer patients, so it's hard to apply the results to the general population in clinical practice. Also 5 studies had less than 100 subjects included, and 18-week study was the longest one among studies reviewed in this paper. Therefore, large and long-term clinical studies with the general population should be conducted to use venlafaxine for the treatment of hot flashes in clinical practice.

주제어

AI 본문요약
AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

문제 정의

Among the antidepressants studied for management of hot flashes, venlafaxine is the agent investigated the most. The aim of this study is to assess the effect of venlafaxine on hot flashes by performing a systematic analysis. A MEDLINE search (from January 1990 to July 2010) was conducted using a combination search term hot flashes and venlafaxine with limits of randomized controlled trials and humans.

제안 방법

Researchers randomized patients to one of three treatments: venlafaxine 75 mg/day (n=102), medroxyprogesterone 20 mg/day (n=108), or cyproterone acetate 100 mg/day (n=101). All participants received two indistinguishable pills in the morning and one in the evening from week 1 to week 8, and then one in the morning and one in the evening from week 9 to week 10. This method made this study comply with the double-blind design considering the gradual discontinuation of venlafaxine (given at half-dose, 37.
All participants received two indistinguishable pills in the morning and one in the evening from week 1 to week 8, and then one in the morning and one in the evening from week 9 to week 10. This method made this study comply with the double-blind design considering the gradual discontinuation of venlafaxine (given at half-dose, 37.5 mg/day in weeks 9 and 10). After 4 weeks of treatment, the median hot flash scores decreased significantly from baseline in all three treatment groups (p<0.
¹⁵⁾ Women with a history of breast cancer were included, and they had to have daily hot flashes (≥1 per day). This study consisted of the low-dose study and the high-dose study. In the low-dose study, 52 participants were randomized to one of two different sequence groups: venlafaxine/placebo or placebo/venlafaxine.

대상 데이터

There are limitations in this study. The treatment period of this study was short, and participants were primarily breast cancer survivors. Therefore, longer studies with general population should be conducted to use venlafaxine for the treatment of hot flashes in clinical practice.

성능/효과

After 4 weeks of treatment, the median hot flash scores decreased significantly from baseline in all three treatment groups (p<0.0001).
At week 4, the median hot flash scores significantly decreased from baseline (p<0.001 for comparison of the treatment groups with the placebo group) by 27% (95% CI, 11-34) in the placebo group (n=50), 37% (95% CI, 26-54) in the 37.5 mg/day group (n=49), 61% (95% CI, 50-68) in the 75 mg/day group (n=43), and 61% (95% CI, 48-75) in the 150 mg/day group (n=49).
During the study period, hot flash scores decreased significantly in the venlafaxine group, but MPA was more effective than venlafaxine in reducing hot flash scores (at week 6, mean reductions from baseline: 79% in the MPA group, 55% in the venlafaxine group, p<0.0001).
However, many health care providers now want to use nonhormonal therapies for patients with hot flashes because of the results of the Women’s Health Initiative study in 2002. The study showed increased rates of breast cancer, coronary artery disease, stroke, and pulmonary embolism in women treated with estrogenprogestin versus placebo. The exact cause of hot flashes is still unknown, but histamine, prostaglandins, serotonin, acetaldehyde, and substance P are proposed mediators of hot flashes.

참고문헌 (19)

Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000; 36: 155-164.

상세보기
Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas 1997; 27: 203-214.

상세보기
Kronenberg F, Downey J. Thermoregulatory physiology of menopausal hot flashes. Canadian J Physiol Pharmacol 1987; 65: 1312-1322.

상세보기
Rossouw JE, Anderson GL, Prentice RL, et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.

상세보기
Lomax P, Schonbaum E. Postmenopausal hot flushes and their management. Pharm Ther 1993; 57: 347-358.

상세보기
Freedman RR, Woodward S, Sabharwal SC. Alpha 2-adrenergic mechanism in menopausal hot flushes. Obstet Gynecol 1990; 76: 573-578.

상세보기
$Effexor^{\circledR}$ prescribing information. Wyeth Pharmaceuticals. 2009.
Venlafaxine hydrochloride. In: AHFS Drug Information. American Society of Health-System Pharmacists. 2010.
Venlafaxine. In: Drug Information Handbook. Lexi- $Comp^{\circledR}$ . 2008.
Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57: 503-509.

상세보기
Tran PV, Bymaster FP, McNamara RK, et al., Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23: 78-86.

상세보기
Loprinzi CL, Kugler JW, Sloan JA, et al., Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059-2063.

상세보기
Evans ML, Pritts E, Vittinghoff E, et al., Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105: 161-166.

상세보기
Loprinzi CL, Levitt R, Barton D, et al., Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 2006; 24: 1409-1414.

상세보기
Carpenter JS, Storniolo AM, Johns S, et al., Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 2007; 12: 124-135.

상세보기
Loibl S, Schwedler K, von Minckwitz G, et al., Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. Ann Oncol 2007; 18: 689-693.

상세보기
Buijs C, Mom CH, Willemse PH, et al., Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2009; 115: 573-580.

상세보기
Irani J, Salomon L, Oba R, et al., Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11: 147-154.

상세보기
Walker EM, Rodriguez AI, Kohn B, et al., Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010; 28: 634-640.

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Venlafaxine의 안면홍조 증상개선효과에 대한 최근 연구 고찰
Venlafaxine for Management of Hot Flashes: A Review of Randomized Controlled Trials in Human 원문보기

초록
AI-Helper

Abstract ▼ AI-Helper

주제어

AI 본문요약
AI-Helper

문제 정의

제안 방법

대상 데이터

성능/효과

참고문헌 (19)

이 논문을 인용한 문헌

저자의 다른 논문 :

관련 콘텐츠

원문 보기

원문 URL 링크

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트

연합인증

Venlafaxine의 안면홍조 증상개선효과에 대한 최근 연구 고찰 Venlafaxine for Management of Hot Flashes: A Review of Randomized Controlled Trials in Human 원문보기

초록 용어보기논문에서 용어와 풀이말을 자동 추출한 결과로, 시범 서비스 중입니다. AI-Helper

Abstract ▼ AI-Helper

주제어

AI 본문요약 엑셀 다운로드 AI-Helper

문제 정의

제안 방법

대상 데이터

성능/효과

참고문헌 (19)

이 논문을 인용한 문헌

저자의 다른 논문 :

이유정 (15)

관련 콘텐츠

원문 보기

원문 URL 링크

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트

Venlafaxine의 안면홍조 증상개선효과에 대한 최근 연구 고찰
Venlafaxine for Management of Hot Flashes: A Review of Randomized Controlled Trials in Human 원문보기

초록
AI-Helper

AI 본문요약
AI-Helper